In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tego BioSciences Corp.

Division of Arrowhead Pharmaceuticals Inc.

Latest From Tego BioSciences Corp.

Start-Up Previews (2/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Small Size=Big Potential , features profiles of C Sixty Inc., engeneOS Inc., Nanospectra Biosciences Inc. and Oxonica Ltd., Plus these Selected Start-Ups across Health Care: Addiction Therapies Inc., ImpactRx Inc., Ingenium Pharmaceuticals AG and Insulet Corp.

C Sixty Inc.

C Sixty Inc. aims to find commercial applications for Buckminsterfullerene, a sixty-carbon atom (C60) molecule and only the third form of elemental carbon found in nature, at the intersection of nano- and biotechnologies. According to the company's CEO, Uri Sagman, these soccer ball-shaped and nanometer-sized Buckyballs have potential futures as therapeutics, drug delivery scaffolds, and components of medical devices and diagnostics. Furthest along in the C Sixty pipeline are an anti-HIV protease compound and a compound designed to treat neurodegenerative disorders.
BioPharmaceutical Business Strategies

Nanotechnology: Small Size Equals Big Potential

The ability to manipulate materials and create structures at the molecular level is spurring research in a spectrum of fields--from computing, materials science, and manufacturing, to medicine and diagnostics. Much of the work is still being done in academic laboratories and in big corporations with no near-term plans to launch nano-products. But lately, several new companies have been forming, convinced they can turn blue-sky nanotechnology research into greenback dollars. Their goals range from the deliberately practical to the decidedly high-risk but potentially paradigm-shifting.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Neurology, Nervous System
  • Alias(es)
  • C Sixty Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Arrowhead Pharmaceuticals Inc.
  • Senior Management
  • Russ Lebovitz, MD, PhD, CEO
    MyPhuong Lam, Dir. of Fin.
    Russ Lebovitz, MD, PhD, Pres.
    Andreas Hirsch PhD, PhD, CSO
    Virginia Dadey, VP, Bus. Dev.
  • Contact Info
  • Tego BioSciences Corp.
    Phone: (626) 304-3400
    201 South Lake Ave.
    Ste. 703
    Pasadena, CA 91101